[go: up one dir, main page]

DK4360713T3 - Quinazolinderivater som antitumormidler - Google Patents

Quinazolinderivater som antitumormidler Download PDF

Info

Publication number
DK4360713T3
DK4360713T3 DK23219357.3T DK23219357T DK4360713T3 DK 4360713 T3 DK4360713 T3 DK 4360713T3 DK 23219357 T DK23219357 T DK 23219357T DK 4360713 T3 DK4360713 T3 DK 4360713T3
Authority
DK
Denmark
Prior art keywords
antitumor agents
quinazoline derivatives
quinazoline
derivatives
antitumor
Prior art date
Application number
DK23219357.3T
Other languages
English (en)
Inventor
Ding Zhou
Ziqiang Cheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK4360713T3 publication Critical patent/DK4360713T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK23219357.3T 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler DK4360713T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018106098 2018-09-18
CN2019091078 2019-06-13
EP19862146.8A EP3853220B1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
DK4360713T3 true DK4360713T3 (da) 2025-01-06

Family

ID=69888359

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19862146.8T DK3853220T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler
DK23219357.3T DK4360713T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19862146.8T DK3853220T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler

Country Status (19)

Country Link
US (2) US11723908B2 (da)
EP (3) EP4360713B1 (da)
JP (2) JP7546550B2 (da)
KR (1) KR20210061329A (da)
CN (2) CN112654612A (da)
AU (2) AU2019341273B2 (da)
CA (1) CA3099776A1 (da)
DK (2) DK3853220T3 (da)
ES (2) ES3007082T3 (da)
FI (2) FI3853220T3 (da)
HR (2) HRP20241743T1 (da)
HU (2) HUE069764T2 (da)
LT (2) LT3853220T (da)
PL (2) PL4360713T3 (da)
PT (2) PT3853220T (da)
RS (2) RS65413B1 (da)
SI (2) SI4360713T1 (da)
SM (1) SMT202400524T1 (da)
WO (1) WO2020057511A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778589B1 (en) * 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技（上海）有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
TWI820414B (zh) * 2020-04-17 2023-11-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、製備方法及其應用
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
AU2022235956A1 (en) * 2021-03-19 2023-10-05 Beijing Scitech-Mq Pharmaceuticals Limited Quinazoline-based compound, composition, and application of quinazoline-based compound
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
US20240300946A1 (en) * 2021-06-22 2024-09-12 Blueprint Medicines Corporation Egfr inhibitors
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240308981A1 (en) * 2021-06-22 2024-09-19 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240382483A1 (en) * 2021-06-22 2024-11-21 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN115894455B (zh) * 2021-09-30 2024-04-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CN119317625A (zh) * 2021-10-20 2025-01-14 豪夫迈·罗氏有限公司 喹唑啉衍生物的结晶形式、其制备、组合物和用途
WO2023138675A1 (zh) * 2022-01-21 2023-07-27 默达药物（香港）有限公司 喹啉化合物及其用途
KR20250009417A (ko) * 2022-03-14 2025-01-17 후야바이오 인터내셔널, 엘엘씨 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
CN118715216A (zh) * 2022-03-28 2024-09-27 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
WO2024249642A1 (en) * 2023-06-02 2024-12-05 Acerand Therapeutics (Hong Kong) Limited Egfr inhibitors
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491675A1 (en) 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
DE60108754T2 (de) 2000-06-22 2005-06-23 Pfizer Products Inc., Groton Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004000529A1 (de) 2002-06-24 2003-12-31 Fagerdala Deutschland Gmbh Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN103664802B (zh) 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
ATE507224T1 (de) * 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
CN101611041A (zh) * 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
CN107141293B (zh) 2016-03-01 2022-09-23 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
ES2873377T3 (es) 2016-09-22 2021-11-03 Inst Nat Sante Rech Med Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón
EP3677583A4 (en) 2017-09-01 2021-07-21 Shanghai Pharmaceuticals Holding Co., Ltd. NITROGENOUS HETEROCYCLIC COMPOUND, METHOD OF PREPARATION, INTERMEDIATE, COMPOSITION AND APPLICATION
WO2019120213A1 (zh) * 2017-12-19 2019-06-27 南京明德新药研发股份有限公司 喹唑啉衍生物及其应用
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
CN112105618B (zh) * 2018-05-08 2022-05-31 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用

Also Published As

Publication number Publication date
PT3853220T (pt) 2024-02-22
JP2024164018A (ja) 2024-11-26
RS66314B1 (sr) 2025-01-31
EP3853220A4 (en) 2022-06-22
EP4360713A3 (en) 2024-05-22
EP3853220A1 (en) 2021-07-28
CN112654612A (zh) 2021-04-13
SMT202400524T1 (it) 2025-01-14
LT3853220T (lt) 2024-03-12
DK3853220T3 (da) 2024-03-04
FI3853220T3 (fi) 2024-02-22
CA3099776A1 (en) 2020-03-26
PL4360713T3 (pl) 2025-06-23
FI4360713T3 (fi) 2024-12-27
PT4360713T (pt) 2025-01-07
KR20210061329A (ko) 2021-05-27
EP4523755A2 (en) 2025-03-19
JP2022501338A (ja) 2022-01-06
LT4360713T (lt) 2025-01-10
SI4360713T1 (sl) 2025-02-28
EP3853220B1 (en) 2024-01-03
WO2020057511A1 (en) 2020-03-26
HUE069764T2 (hu) 2025-04-28
AU2019341273B2 (en) 2024-09-26
US20230293533A1 (en) 2023-09-21
HRP20241743T1 (hr) 2025-02-28
HRP20240293T1 (hr) 2024-05-24
EP4360713B1 (en) 2024-10-30
AU2019341273A1 (en) 2020-11-19
ES2971927T3 (es) 2024-06-10
CN118255772A (zh) 2024-06-28
EP4360713A2 (en) 2024-05-01
PL3853220T3 (pl) 2024-09-02
JP7546550B2 (ja) 2024-09-06
US20210386742A1 (en) 2021-12-16
US11723908B2 (en) 2023-08-15
ES3007082T3 (en) 2025-03-19
HUE065578T2 (hu) 2024-06-28
EP4523755A3 (en) 2025-06-11
AU2024204847A1 (en) 2024-08-01
RS65413B1 (sr) 2024-05-31
SI3853220T1 (sl) 2024-04-30

Similar Documents

Publication Publication Date Title
DK4360713T3 (da) Quinazolinderivater som antitumormidler
PT3958977T (pt) Derivados de camptotecina
IL292161A (en) New methylquinazolinone derivatives
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
PL3897842T3 (pl) Pochodne bicykliczne
LT3830085T (lt) Deuterinti lanifibranoro dariniai
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
EP3718545A4 (en) ANTI-TUMOR AGENT
ME03466B (me) Antitumorska jedinjenja
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK4056557T3 (da) Benzazepinderivater nyttige som medikamenter
DK3894410T3 (da) Substituerede xanthinderivater
EP3595647A4 (en) ARYL-PIPERIDINE DERIVATIVES
DK3484875T3 (da) Pyrazolylaminobenzimidazolderivater som JAK-hæmmere
EP3914359A4 (en) SALICYLAMINE DERIVATIVES RELATED TO TRIPHENYLPHOSPHONIUM
EP3782983A4 (en) ISOINDOLE DERIVATIVE
DK3770162T3 (da) Dihydrochromenderivater
EP4062972A4 (en) PYRAZOLOMORPHINAN DERIVATIVE
HK40108721A (en) Quinazoline derivatives as antitumor agents